Agricultural Genomics Deals
This article was originally published in Start Up
Unlike the human genomics company deals with pharmaceutical companies, there is a small and ever-shrinking list of potential corporate partners in agricultural genomics. Exclusivity is an essential element; there isn't an analog in the agricultural field to the non-exclusive platform technology-sharing deals pioneered in the human genomics field by companies such as Incyte Pharmaceuticals and Genome Therapeutics Corp.
You may also be interested in...
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?
Biomarkers are being used now across the whole pharmaceutical value chain, but it's unlikely we'll see a surge in the number of VC-backed biomarker discovery start-ups until the business models are proven.